Alexandra Glucksmann
Director/Board Member at REGENXBIO INC.
Net worth: 113 290 $ as of 2024-02-28
Profile
Presently, Alexandra Glucksmann holds the position of Chairman at Women Entrepreneurs In Science & Technology and President & Chief Executive Officer of Sensorium Therapeutics, Inc. Dr. Glucksmann is also on the board of REGENXBIO, Inc. and Scenic Biotech BV.
In the past she occupied the position of Chief Executive Officer & Director at Cedilla Therapeutics, Inc., Chief Operating Officer of Editas Medicine, Inc., Vice President-Technology for Millennium Pharmaceuticals, Inc. and Senior Vice President-Research & Development at Cerulean Pharma, Inc.
Dr. Glucksmann received a doctorate from The University of Chicago and an undergraduate degree from the University of Wisconsin.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
REGENXBIO, INC.
0.01% | 2023-06-01 | 6,496 ( 0.01% ) | 113 290 $ | 2024-02-28 |
Alexandra Glucksmann active positions
Companies | Position | Start |
---|---|---|
REGENXBIO INC. | Director/Board Member | 2018-05-24 |
Women Entrepreneurs In Science & Technology | Chairman | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Director/Board Member | 2017-08-31 |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | Chief Executive Officer | 2023-12-03 |
Former positions of Alexandra Glucksmann
Companies | Position | End |
---|---|---|
EDITAS MEDICINE, INC. | Chief Operating Officer | 2017-02-28 |
Taconic Biosciences, Inc.
Taconic Biosciences, Inc. Agricultural Commodities/MillingProcess Industries Taconic Biosciences, Inc. provides research rodents and related products and services. It offers monoclonal antibody production, drug safety testing and other services. The firm also provides contract breeding solutions, animal models, Taconic transgenic exchange, custom model generation, contract research solutions, and research services. The company was founded by Robert K. Phelan in 1949 and is headquartered in Rensselaer, NY. | Director/Board Member | 2015-04-30 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 2013-05-31 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Training of Alexandra Glucksmann
The University of Chicago | Doctorate Degree |
University of Wisconsin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
REGENXBIO INC. | Health Technology |
EDITAS MEDICINE, INC. | Health Technology |
Private companies | 7 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Taconic Biosciences, Inc.
Taconic Biosciences, Inc. Agricultural Commodities/MillingProcess Industries Taconic Biosciences, Inc. provides research rodents and related products and services. It offers monoclonal antibody production, drug safety testing and other services. The firm also provides contract breeding solutions, animal models, Taconic transgenic exchange, custom model generation, contract research solutions, and research services. The company was founded by Robert K. Phelan in 1949 and is headquartered in Rensselaer, NY. | Process Industries |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Women Entrepreneurs In Science & Technology | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | Health Technology |